Eriko Aotani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eriko Aotani has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Masahiro Takeuchi
Department of Clinical Medicine, School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo, 108-8641, Japan
2 shared publications - Aikou Okamoto
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo 105-8461, Japan
1 shared publication - Aikou Okamoto
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan
1 shared publication - Akihiko Gemma
Nippon Medical School Tokyo Japan
1 shared publication - Amit Manulal Oza
Princess Margaret Cancer Centre 2 Division of Medical Oncology and Hematology , Toronto, Canada
1 shared publication - Anne Lanceley
Dept. of Women's Cancer, UCL Elizabeth Garrett Anderson Institute for Women's Health, University College London, London, United Kingdom
1 shared publication
Latest Publications
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 5508
Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS).
5508Background: 110 (19%) of the 570 women with PRROC enrolled in SBS stopped chemotherapy within 8 weeks. We sought to identify baseline characteristics, including QOL and clinical factors, that were associated with overall survival and stopping chemotherapy early. Methods: QOL domains were measured with the EORTC QLQ-C30 and QLQ-OV28. QLQ-C30 subscales were dichotomised using cut-points recommended by Diouf et al (The Oncologist 2015). Cox’s Proportional Hazards regression was used to assess univariable and multivariable associations with overall survival. Clinical factors for the multivariable model were selected using backward elimination; candidate variables included those with P<0.05 in univariable analyses. The association between baseline QOL domains and stopping chemotherapy early was determined by categorising the QOL domains and using a chi-squared test. Results: Univariable analyses of baseline QOL data (N=545) showed that physical function (PF), role function (RF), global health status (GHS) ...
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 5508
Baseline quality of life (QOL) as a predictor of stopping chemotherapy early, and of overall survival, in platinum-resistant/refractory ovarian cancer (PRROC): The GCIG symptom benefit study (SBS).
5508Background: 110 (19%) of the 570 women with PRROC enrolled in SBS stopped chemotherapy within 8 weeks. We sought to identify baseline characteristics, including QOL and clinical factors, that were associated with overall survival and stopping chemotherapy early. Methods: QOL domains were measured with the EORTC QLQ-C30 and QLQ-OV28. QLQ-C30 subscales were dichotomised using cut-points recommended by Diouf et al (The Oncologist 2015). Cox’s Proportional Hazards regression was used to assess univariable and multivariable associations with overall survival. Clinical factors for the multivariable model were selected using backward elimination; candidate variables included those with P<0.05 in univariable analyses. The association between baseline QOL domains and stopping chemotherapy early was determined by categorising the QOL domains and using a chi-squared test. Results: Univariable analyses of baseline QOL data (N=545) showed that physical function (PF), role function (RF), global health status (GHS) ...
- 15 February 2016
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 21 (5) , 836-842
Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer
In the CATS (Cisplatin And TS-1) randomized trial comparing cisplatin plus either docetaxel (DP arm) or TS-1 (SP arm) in lung cancer, efficacy was found to be equivalent but the global quality of life (QOL) score was higher in the SP arm. The purpose of the current study was to identify which of the adverse events (AEs) contributed to the deterioration of QOL. QOL and AE data from the CATS trial were used to quantitatively analyze the relationship between deterioration of QOL score and occurrence of AEs. Subtracted values of the QOL score from post-chemotherapy to pre-chemotherapy were fully compared between patients with or without each AE (Student’s t test, significance level = 0.001). Multivariate linear regression analysis was also performed. Analysis of variance was performed to identify whether grade of AE(s) might be significantly correlated with the deterioration of the QOL score (significance level of 0.05). As expected, gastrointestinal (GI) toxicities were associated with worsening of a variety of QOL items in both trial arms, detected by both univariate and multivariate analysis (p < 0.001 and p < 0.0001, respectively). Multivariate analysis unpredictably indicated that an increase in serum bilirubin level was the only AE that was uniquely associated with worsening of physical functioning (p = 0.0002), cognitive functioning (p < 0.0001), and financial problems (p = 0.0005) in the DP arm, although not in the SP arm. GI toxicities tended to be prolonged in the SP arm. An increase in serum bilirubin level may contribute to the worse global QOL of subjects in the DP arm in the CATS trial. The method we used here may be a unique approach to identify unpredictable AE(s) that worsen the QOL of patients treated by chemotherapy.
- 15 February 2016
- Published by Springer Nature in International Journal of Clinical Oncology
- Vol. 21 (5) , 836-842
Identification of adverse events that have a negative impact on quality of life in a clinical trial comparing docetaxel versus S-1 with cisplatin in lung cancer
In the CATS (Cisplatin And TS-1) randomized trial comparing cisplatin plus either docetaxel (DP arm) or TS-1 (SP arm) in lung cancer, efficacy was found to be equivalent but the global quality of life (QOL) score was higher in the SP arm. The purpose of the current study was to identify which of the adverse events (AEs) contributed to the deterioration of QOL. QOL and AE data from the CATS trial were used to quantitatively analyze the relationship between deterioration of QOL score and occurrence of AEs. Subtracted values of the QOL score from post-chemotherapy to pre-chemotherapy were fully compared between patients with or without each AE (Student’s t test, significance level = 0.001). Multivariate linear regression analysis was also performed. Analysis of variance was performed to identify whether grade of AE(s) might be significantly correlated with the deterioration of the QOL score (significance level of 0.05). As expected, gastrointestinal (GI) toxicities were associated with worsening of a variety of QOL items in both trial arms, detected by both univariate and multivariate analysis (p < 0.001 and p < 0.0001, respectively). Multivariate analysis unpredictably indicated that an increase in serum bilirubin level was the only AE that was uniquely associated with worsening of physical functioning (p = 0.0002), cognitive functioning (p < 0.0001), and financial problems (p = 0.0005) in the DP arm, although not in the SP arm. GI toxicities tended to be prolonged in the SP arm. An increase in serum bilirubin level may contribute to the worse global QOL of subjects in the DP arm in the CATS trial. The method we used here may be a unique approach to identify unpredictable AE(s) that worsen the QOL of patients treated by chemotherapy.